NCT04882098

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,054 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Conditions

• Arthritis, Psoriatic

Interventions

Type	Name	Description
DRUG	Guselkumab	Participants will receive guselkumab as SC injection.
DRUG	Placebo	Participants will receive matching placebo as SC injection.

Timeline

• Start date: 2021-06-17
• Primary completion: 2024-12-30
• Completion: 2027-10-05
• First posted: 2021-05-11
• Last updated: 2026-04-13
• Results posted: 2026-02-04

Locations

280 sites across 29 countries: United States, Australia, Bosnia and Herzegovina, Bulgaria, Canada, China, Croatia, Czechia, Estonia, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Philippines, Poland, Russia, Serbia, Slovakia, Slovenia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine

Regulatory

• FDA-regulated drug study